LEUKOTRIENE A4-HYDROLASE INHIBITORS Russian patent published in 2019 - IPC C07D205/04 A61K31/397 A61P17/00 A61P11/06 A61P9/10 A61P1/04 A61P29/00 A61P11/02 A61P37/06 A61P11/08 A61P31/00 

FIELD: chemistry.

SUBSTANCE: invention relates to a novel compound of formula (I) or a pharmaceutically acceptable salt thereof, having the properties of LTA-4-hydrolase inhibitor. Compounds can be used for treating a disease and disorder, which is facilitated by inhibiting LTA4-h activity. Said disease or disorder is selected from a group consisting of acute or chronic inflammation, cystic fibrosis, septic shock, acute respiratory distress syndrome, chronic obstructive pulmonary disease, inflammatory bowel disease, selected from a group consisting of nonspecific ulcerative colitis, and Crohn's disease, and postoperative trauma and post-transplant arteriosclerosis, inflammatory disorder of the lungs and respiratory tracts selected from a group consisting of asthma, chronic bronchitis, bronchiolitis, obliterating bronchiolitis, allergic airway inflammation, eosinophilic granuloma, pneumonia, pulmonary fibrosis, pulmonary manifestations of connective tissue diseases, acute or chronic pulmonary injury, chronic obstructive pulmonary disease, acute respiratory distress syndrome in adults and other non-infectious inflammatory lung disorders characterized by eosinophilic infiltration. In formula (I)

,

R is group where r is 0; q is 1; R^1a is chlorine or hydrogen; R^1b, R^1c, R^1d and R^1e each represent hydrogen; R³ is -O-; R⁴ represents a direct link; R^5a and R^6a each independently represent hydrogen; R⁷ is -C (R^5b)₂-R¹⁵; each R^5b independently represents hydrogen; R¹⁵ is phenyl optionally substituted with a C(O)OR¹⁰ group; each R¹⁰ is hydrogen or C₁-C₄ alkyl; and R¹⁴ is:

where R¹⁷ is selected from a group consisting of hydrogen and C(O)OR¹⁰.

EFFECT: compounds can be used for treating diseases and disorders by inhibiting LTA4-h activity.

22 cl, 2 tbl, 10 ex